Section of Allergy and Clinical Immunology, Imperial College London, NHLI, Royal Brompton Hospital, London SW3 6LY, UK.
Curr Allergy Asthma Rep. 2013 Aug;13(4):371-80. doi: 10.1007/s11882-013-0359-7.
Recombinant allergens for immunotherapy aim to overcome the problems of natural extracts as they can be produced in unlimited amounts with exact physiochemical and immunological properties. These can be modified to have more favourable characteristics including reduced IgE reactivity or enhanced immunogenicity. Different types of recombinant allergens have been evaluated in clinical phase II and III trials whilst others are currently under development. In this review, we identified double-blind, placebo-controlled randomised clinical trials assessing the efficacy and safety of various recombinant allergen preparations. The majority of studies have up to now focused on cat, grass, birch, ragweed and bee venom allergens. Some studies have shown some of these preparations to be effective and well tolerated. However, there are still outstanding issues regarding optimum doses, minimising side effects and long-term effects.
用于免疫治疗的重组变应原旨在克服天然提取物的问题，因为它们可以无限量地生产，具有确切的理化和免疫学特性。这些可以进行修饰，以具有更有利的特性，包括降低 IgE 反应性或增强免疫原性。不同类型的重组变应原已在临床 II 期和 III 期试验中进行了评估，而其他一些正在开发中。在这篇综述中，我们确定了双盲、安慰剂对照随机临床试验，评估了各种重组变应原制剂的疗效和安全性。迄今为止，大多数研究都集中在猫、草、桦树、豚草和蜂毒变应原上。一些研究表明，其中一些制剂是有效且耐受良好的。然而，在最佳剂量、最小化副作用和长期效果方面仍存在悬而未决的问题。
